New York State Common Retirement Fund’s Roivant Sciences ROIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.96M Buy
281,459
+31,822
+13% +$940K 0.01% 783
2026
Q1
$6.91M Buy
249,637
+14,000
+6% +$360K 0.01% 885
2025
Q4
$5.11M Buy
235,637
+6,600
+3% +$130K 0.01% 1028
2025
Q3
$3.47M Buy
229,037
+46,344
+25% +$574K ﹤0.01% 1226
2025
Q2
$2.06M Sell
182,693
-8,700
-5% -$94.3K ﹤0.01% 1402
2025
Q1
$1.93M Sell
191,393
-28,400
-13% -$307K ﹤0.01% 1386
2024
Q4
$2.6M Buy
219,793
+29,000
+15% +$343K ﹤0.01% 1325
2024
Q3
$2.2M Sell
190,793
-26,200
-12% -$298K ﹤0.01% 1380
2024
Q2
$2.29M Buy
216,993
+206
+0.1% +$2.26K ﹤0.01% 1427
2024
Q1
$2.28M Sell
216,787
-51,305
-19% -$553K ﹤0.01% 1422
2023
Q4
$3.01M Sell
268,092
-64,221
-19% -$626K ﹤0.01% 1296
2023
Q3
$3.88M Buy
332,313
+9,217
+3% +$104K 0.01% 1209
2023
Q2
$3.26M Buy
323,096
+310,925
+2,555% +$2.78M ﹤0.01% 1334
2023
Q1
$89.8K Buy
+12,171
New +$100K ﹤0.01% 2841

Other funds holding ROIV

New York State Common Retirement Fund's ROIV Position: Q2 2026 in Review

New York State Common Retirement Fund increased its Roivant Sciences (ROIV) stake by 13% in Q2 2026, buying an estimated $940K and bringing the position to 281,459 shares worth $9.96M. The position accounts for 0.01% of the portfolio, ranked #783.

New York State Common Retirement Fund first reported a position in ROIV in Q1 2023 and has held it in 14 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • New York State Common Retirement Fund held 281,459 shares of Roivant Sciences worth $9.96M as of Q2 2026.
  • New York State Common Retirement Fund bought 31,822 Roivant Sciences shares in Q2 2026, an estimated $940K.
  • Roivant Sciences made up 0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #783 holding.
  • New York State Common Retirement Fund first reported a position in Roivant Sciences in Q1 2023 and has held it in 14 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.